Ann: Presentation of BIT225-009 HIV-1 Phase 2 Data, page-587

Hi , I am here only since few weeks , small investor ( 11,000 shares ) . I am in USA and investing for few years in

Pro 140 ( Leronlimab )

New preliminary results in monotherapy with once a week SC self-administer injection just showed 92% patients with

VL < 50 copies/ml , and not one serious side effect for many years now . !!!!! Not one , in contrary to HAART treatment.

I am thinking that since BIT225 reducing virus in reservoir cells ,( hopefully reducing HIV dementia ) ,  maybe it will be  a good combination with Leronlimab for many patients.